How to Select the Bi-Specific mAb For the Treatment of RRMM?

Time: 2:00 pm
day: Day Two

Details:

  • Patient and disease-based factors should drive the treatment decision making
  • Bi-specific mAbs are off the shelf-drugs that will present wide availability
  • Bi-specific mAbs might be combined wih other mABs or IMiD’s to complement the treatment strategies and improve outcomes

Speakers: